Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation

Journal of Internal Medicine

Volumn 258, Issue 2, 2005, Pages 133-144

  Indredavik, Bent ^a   Rohweder, G ^a   Lydersen, S ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PRIORITY JOURNAL; RATING SCALE; RISK REDUCTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WARFARIN;

EID: 22644433216     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01512.x     Document Type: Article

References (40)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-73.
3. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke 1985; 16: 182-8.
4. Glader EL, Stegmayr B, Norrving B et al. for the Risk-stroke Collaboration. Large variation in the use of oral anticoagulation in stroke patients with atrial fibrillation: a Swedish national perspective. J Intern Med 2004; 255: 22-32.
5. Steger C, Pratter A, Martinek-Bregel M et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Australian Stroke registry. Eur Heart J 2004; 25: 1734-40.
6. Bogousslavsky J, Van Melle G, Regli F, Kappenberger I. Pathogensis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology 1990; 40: 1046-50.
7. Mannin WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995; 155: 2193-8.
8. Gustafsson C, Britton M. Pathogenetic mechanism of stroke in non-valvular atrial fibrillation: follow-up of stroke patients with and without atrial fibrillation. J Intern Med 1991; 230: 11-6.
9. Longstreth WT Jr, Bernick C, Fitzpatrick A et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 2001; 56: 368-75.
10. Sandercock P, Bamford J, Dennis M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: 1460-5.
11. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA. Stroke severity in patients with atrial fibrillation. Am J Med 2002; 112: 572-4.
12. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996; 27: 1760-4.
13. Atrial Fibrillation Investigators, Atrial fibrillation, Aspirin, Anticoagulation Study, Boston Area Anticoagulation Trial for Atrial Fibrillation Study et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
14. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy in atrial fibrillation: a meta analyses. Ann Internal Med 1999; 131: 492-501.
15. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
16. Segal JB, McNamara RL, Miller MR et al. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation in the primary prevention of ischemic stroke. In: The Cochrane Library, Issue 3. Oxford: Update Software 2002.
17. Hylec EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylatic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
18. Bogousslavsky J, Kaste M, Skyhoj Olsen T, Hacke W, Orgogozo JM for the EUSI Executive Committee. Risk factors and stroke prevention. Cerebrovasc Dis 2000; 10 (Suppl. 3): 12-21.
19. Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke; a statement from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163-82.
20. Laupacis A, Albers G, Dalen J et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114 (Suppl.) 579S-89S.
21. Hart RG, Pearce LA, Miller VT et al. Cardioembolic vs. non-cardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the Stroke Prevention in Atrial Fibrillation studies. Cerebrovasc Dis 2000; 10: 39-43.
22. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-8.
23. Hylec EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation for stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
24. Indredavik B, Bakke F, Slørdahl SA, Rokseth R, Håheim LL. Treatment in a combined acute and rehabilitation stroke unit: which aspects are most important? Stroke 1999; 30: 917-23.
25. Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scot Med J 1957; 2: 118-23.
26. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke 1985; 16: 885-90.
27. Ellekjær H, Holmen J, Indredavik B, Tere'nt A. Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Stroke 1997; 28: 2180-4.
28. Lin HJ Wolf PA, Benjamin EJ, Belanger AJ, D'Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. Stroke 1995; 26: 1527-30.
29. Go AS, Hylec EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-92.
30. Yamaguchi T for Japanese nonvalvular atrial fibrillation-embolism secondary prevention cooperative study group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. Stroke 2000; 31: 817-21.
31. Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation. Chest 2004; 126: 1938-45.
32. Evans A, Kalra I. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001; 161: 1443-7.
33. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
34. Thomassen G, Hansen MS, Nordoy A, Hansen JB. Antithrombotic treatment of atrial fibrillation in hospital. Tidsskr Nor legeforen 2001; 121: 2800-4.
35. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
36. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch intern Med 2000; 160: 41-6.
37. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van der Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulation therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomised clinical trial. Arch Intern Med 2003; 163: 2639-46.
38. Hallan S, Åsberg A, Indredavik B, Widrøe TE. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different outcomes. J Intern Med 1999; 246: 309-16.
39. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996; 156: 1829-36.
40. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke' LÅ. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-60.